MedTrace Logo

Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE

NCT03752983 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2019-01-29

No results posted yet for this study

Summary

Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt production of autoreactive antibodies.The chemokine CXC ligand 13 protein (CXCL13), also known as B cell-attracting chemokine-1 (BAC-1) or B lymphocyte chemoattractant (BLC), CXCL13 serum levels were correlated with disease activity using the SLE Disease Activity Index (SLEDAI) and to lupus nephritis

Conditions

  • Systemic Lupus

Interventions

DIAGNOSTIC_TEST

blood samples

blood samples

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-03-01
Completion
2020-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03752983 on ClinicalTrials.gov